Sponsored Links
| Survival For High Risk Childhood Leukemia More Than Doubled By New Treatment |
 |
 |
 |
| Medical News - Lymphoma and Leukemia | |||
|
Results of a phase two clinical trial published October 5th in the Journal of Clinical Oncology show that adding continuous daily doses of a targeted drug called imatinib mesylate to regular chemotherapy more than doubled three-year survival rates for children with a high risk type of blood cancer called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Read more: Lymphoma / Leukemia / Myeloma News From Medical News Today
|